NetworkNewsBreaks – VistaGen Therapeutics Inc. (
Post# of 130
(Total Views: 213)
Posted On: 12/10/2020 4:16:11 PM
NetworkNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Granted Patent for Innovative Treatment for MDD
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has been granted a patent by the Korean Intellectual Property Office (“KIPO”) for one of its treatments for depression. VistaGen received notification that KIPO has issued a decision to grant Patent Application No. 10-2015-7020176. The patent relates to VistaGen’s PH10, an investigational neuroactive nasal spray designed to have rapid-onset therapeutic potential in a variety of neuropsychiatric indications involving depression; the patent will not expire earlier than 2034. VistaGen is currently preparing for Phase 2B clinical development of PH10 as a potential stand-alone, rapid-onset treatment for major depressive disorder (“MDD”). “The Republic of Korea is an important pharmaceutical market,” said VistaGen CEO Shawn K. Singh in the press release. “With counterpart patents already issued in the U.S., Greater China , Europe and Japan, this patent enhances our patent protection for PH10 and is a key component of our global commercial protection strategy for PH10.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has been granted a patent by the Korean Intellectual Property Office (“KIPO”) for one of its treatments for depression. VistaGen received notification that KIPO has issued a decision to grant Patent Application No. 10-2015-7020176. The patent relates to VistaGen’s PH10, an investigational neuroactive nasal spray designed to have rapid-onset therapeutic potential in a variety of neuropsychiatric indications involving depression; the patent will not expire earlier than 2034. VistaGen is currently preparing for Phase 2B clinical development of PH10 as a potential stand-alone, rapid-onset treatment for major depressive disorder (“MDD”). “The Republic of Korea is an important pharmaceutical market,” said VistaGen CEO Shawn K. Singh in the press release. “With counterpart patents already issued in the U.S., Greater China , Europe and Japan, this patent enhances our patent protection for PH10 and is a key component of our global commercial protection strategy for PH10.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)VistaGen Therapeutics, Inc. (VTGN) Stock Research Links
Scroll down for more posts ▼